Revolution Medicines Q3 net loss $305.2M; advancing daraxonrasib pivotal trials

Revolution Medicines, Inc.

2025-Q3 EPS reported -$4.06

Net loss $305.2M vs $156.3M YoY; R&D expense $262.5M (+73%), G&A $52.8M (+120%).
Cash, equivalents & securities $1.93B; full-year GAAP net loss guidance reaffirmed at $1.03B-$1.09B.
RASolute 302 (PDAC) enrollment winding down; data readout on track for 2026.
RASolute 304 (adjuvant PDAC) initiated; RASolute 303 (1L metastatic PDAC) expected to start this year.
New CDO Alan Sandler, U.S. GM Alicia Gardner, Europe GM Gerwin Winter appointed.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.